Analysts expect that Prothena Co. PLC (NASDAQ:PRTA) will announce sales of $270,000.00 for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for Prothena’s earnings, with estimates ranging from $200,000.00 to $380,000.00. Prothena posted sales of $170,000.00 in the same quarter last year, which suggests a positive year-over-year growth rate of 58.8%. The company is scheduled to issue its next earnings results on Tuesday, February 13th.
On average, analysts expect that Prothena will report full-year sales of $270,000.00 for the current fiscal year, with estimates ranging from $27.49 million to $27.66 million. For the next financial year, analysts forecast that the company will report sales of $26.14 million per share, with estimates ranging from $900,000.00 to $101.20 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that follow Prothena.
Prothena (NASDAQ:PRTA) last released its earnings results on Tuesday, November 7th. The biotechnology company reported ($1.37) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.41) by $0.04. The firm had revenue of $0.19 million during the quarter, compared to analyst estimates of $0.28 million. Prothena had a negative net margin of 562.19% and a negative return on equity of 34.40%. The business’s revenue was down 33.6% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.26) EPS.
Prothena (NASDAQ:PRTA) opened at $40.10 on Thursday. The company has a market cap of $1,530.00, a PE ratio of -9.46 and a beta of 2.43. Prothena has a 52-week low of $34.85 and a 52-week high of $70.00.
A number of hedge funds and other institutional investors have recently bought and sold shares of PRTA. Schwab Charles Investment Management Inc. increased its stake in Prothena by 6.4% in the second quarter. Schwab Charles Investment Management Inc. now owns 163,681 shares of the biotechnology company’s stock valued at $8,859,000 after acquiring an additional 9,824 shares during the period. Bank of New York Mellon Corp increased its stake in Prothena by 7.8% in the second quarter. Bank of New York Mellon Corp now owns 185,462 shares of the biotechnology company’s stock valued at $10,037,000 after acquiring an additional 13,492 shares during the period. Legal & General Group Plc increased its stake in Prothena by 8.9% in the second quarter. Legal & General Group Plc now owns 13,708 shares of the biotechnology company’s stock valued at $740,000 after acquiring an additional 1,120 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Prothena by 187.5% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,375 shares of the biotechnology company’s stock valued at $129,000 after acquiring an additional 1,549 shares during the period. Finally, Principal Financial Group Inc. increased its stake in Prothena by 4.3% in the second quarter. Principal Financial Group Inc. now owns 6,808 shares of the biotechnology company’s stock valued at $368,000 after acquiring an additional 280 shares during the period.
TRADEMARK VIOLATION WARNING: This report was posted by American Banking News and is the property of of American Banking News. If you are reading this report on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The original version of this report can be viewed at https://www.americanbankingnews.com/2018/01/18/270000-00-in-sales-expected-for-prothena-co-plc-prta-this-quarter.html.
Prothena Company Profile
Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.